4SC AG — Board/Management Information 2009

May 4, 2009

News Details

Corporate | 4 May 2009 08:30

4SC AG announces a change in the Supervisory Board – Dr. Thomas Werner nominated to succeed Dr. Thomas Strüngmann

4SC AG / Change of Personnel

Release of a Corporate News, transmitted by DGAP - a company of EquityStory
AG.
The issuer / publisher is solely responsible for the content of this announcement.

---

Planegg-Martinsried, 04 May 2009 - The Martinsried-based drug discovery and
development company 4SC AG (Frankfurt, Prime Standard: VSC) announced today
that Dr. Thomas Strüngmann, current member of the Supervisory Board,
intends to resign his membership effective at the end of the next annual
shareholders' meeting on 15 June 2009 and has proposed Dr. Thomas Werner as
his successor. Dr. Strüngmann, however, will continue to work closely with
the company in a consulting capacity. The Supervisory Board of 4SC AG has
accepted his resignation and thanked him for his dedication.

Dr. Jörg Neerman, 4SC AG Supervisory Board Chairman, commented on Dr.
Strüngmann's retirement: 'In his period as a member of the Supervisory
Board, Dr. Strüngmann significantly shaped the continued development of the
company towards a drug development firm through his extraordinary industry
expertise. He will remain actively connected with 4SC's corporate
development in the future, both, in a consulting function as well as
through the commitment of Santo Holding as a major 4SC shareholder'.

The nomination of Dr. Thomas Werner as successor of Dr. Strüngmann will be
put forth at the upcoming annual shareholders' meeting. Dr. Werner has over
25 years of experience in the pharmaceutical industry, and served as the
CEO of Glaxo Wellcome Germany and GlaxoSmithKline Germany from 1997 to
2008. Prior to that, between 1990 and 1997, he held a variety of managerial
positions within the pharmaceutical group Bristol-Myers Squibb. Since the
beginning of 2009, he has served as a venture partner in the
internationally-active VC company Venture Partner Inventages. Dr. Werner
additionally serves as a member of the Board of Trustees for the
Paul-Ehrlich Institute and the Robert-Koch-Stiftung.

About 4SC AG:

4SC AG (ISIN DE0005753818) has been listed in the Prime Standard of
Frankfurt Stock Exchange since 15 December 2005. Founded in 1997 and now
with a staff of 85 employees, the company develops novel drug candidates
against inflammatory diseases and cancer. 4SC AG utilises its patent
protected platform, to create a sustainable project pipeline of drug
candidates, which are to be developed up to clinical efficacy in early
clinical phases ('proof of concept') and subsequently partnered with the
pharmaceutical industry in return for advance and milestone payments as
well as royalties. There are currently eight projects in the development
pipeline and a rich pool of further discovery projects. Clinical phase IIa
for the first project for the treatment of rheumatoid arthritis has already
successfully been completed and a clinical phase II trial in IBD (Crohn's
disease) has recently been started. An additional project for the treatment
of various cancers has sucessfully completed a clinical phase I trial and
will commence clinical phase II testing shortly. Further projects are in
advanced pre-clinical stages.
Further information is to be found at www.4sc.com.

Legal Note

This document may contain projections or estimates relating to plans and
objectives relating to our future operations, products, or services; future
financial results; or assumptions underlying or relating to any such
statements; each of which constitutes a forward-looking statement subject
to risks and uncertainties, many of which are beyond our control. Actual
results could differ materially, depending on a number of factors.

For more information please contact:

MC Services
Stefan Riedel
Tel.: +49 (89) 21 02 28 40
eMail: stefan.riedel@mc-services.eu

04.05.2009 Financial News transmitted by DGAP

Language: English
Issuer: 4SC AG
Am Klopferspitz 19a
82152 Martinsried
Deutschland
Phone: +49 (0)89 7007 63-0
Fax: +49 (0)89 7007 63-29
E-mail: public@4sc.com
Internet: www.4sc.de
ISIN: DE0005753818
WKN: 575381
Listed: Regulierter Markt in Frankfurt (Prime Standard); Freiverkehr
in Berlin, Düsseldorf, München, Stuttgart

End of News DGAP News-Service

---